• Calidi Biotherapeutics executed a 1-for-16 reverse stock split of its common stock, effective July 30, 2026.
• Shares began trading on a split-adjusted basis July 31, 2026 on NYSE American under ticker CLDI.
• Move aimed to lift the share price to support continued NYSE American listing, reducing delisting risk tied to listing standards.
• Holdings were converted at 1-for-16, rounded up to whole shares; no fractional shares or cash payments were issued.
• Common stock received a new CUSIP: 320703 507.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-035666), on July 31, 2026, and is solely responsible for the information contained therein.